Item 8.01 Other Events
On January 6, 2022, Hepion Pharmaceuticals, Inc. (the "Company") issued a press
release announcing that the United States Adopted Names Council has adopted the
nonproprietary name "rencofilstat" for the Company's lead drug candidate,
CRV431. A copy of the press release is furnished as Exhibit 99.1 to this Form
8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Hepion Pharmaceuticals, Inc. Press Release dated January 6, 2022
104 Cover Page Interactive Data File. The cover page XBRL tags are embedded
within the inline XBRL document.
-2-
© Edgar Online, source Glimpses